Skip to main content

Table 5 Safety evaluation of rmhTNF combined with cisplatin versus cisplatin alone through thoracic perfusion for treating MPE

From: Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

StudyFever (N)Chest pain (N)Myelosuppression (N)Digestive reaction (N)Liver and kidney dysfunction (N)
Group 1Group 2Group 1Group 2Group 1Group 2Group 1Group 2Group 1Group 2
Do W 2005 [20]21/301/3013/3018/3011/3010/3017/3014/301/301/30
Yanhao W 2006 [13]3/284/284/282/280/282/280/2816/28
Zhijun W [26]5/532/315/532/315/533/314/534/312/532/31
Shimeng F 2010 [22]13/433/308/4318/302/435/303/4315/30
Hua Z 2010 [9]20/340/2422/3420/2415/3414/24
Xiqiang W 2010 [24]5/230/318/239/3116/2321/312/232/31
Haiyan C 2015 [10]2/261/273/264/272/263/274/262/27
Jin L 2015 [12]14/263/296/266/291/261/294/264/292/261/29
Tao H 2016 [23]14/305/3013/3010/307/309/30
Chun W 2016 [19]4/320/32
Hua Z 2017 [21]14/210/1812/2113/1812/2111/18
 P < 0.05P > 0.05P > 0.05P > 0.05P > 0.05
  1. Group 1 rmhTNF injection combined with cisplatin, Group 2 cisplatin alone